A neurosurgeon's viral reel questioning stem cell therapy divided the chat.
Where the group landed: autologous therapy has decent data, allogeneic is early, the overselling is real, and the field needs physician-led evidence before it is regulated out of reach.
Key takeaways
- Separate autologous from allogeneic evidence when counseling patients.
- Physician-led data collection is what keeps these therapies available.
From Buzz in the chat, the longevitydocs™ Sunday newsletter, May 31, 2026. Member discussion, not clinical guidance.
Originally published in The Longevity Medicine Intelligence newsletter.
WRITTEN BYlongevitydocs™ editorsCurated by the longevitydocs™ editorial team from the weekly newsletter
